台灣臨床試驗主持人資料庫|TPIDB

2017-06-02 - 2020-02-28

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓

Taipei Veterans General Hospital

Digestive System Department

2016-02-01 - 2019-05-01

Phase III

A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma

Condition/Disease

Hepatocellular Carcinoma
Test Drug

Nivolumab/Sorafenib

Participate Sites
8Sites

Terminated7Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

彭成元

China Medical University Hospital-Taipei

未分科

2016-07-01 - 2020-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Condition/Disease

NON-SMALL CELL LUNG CANCER (NSCLC)
Test Drug

Atezolizumab (MPDL3280A)

Participate Sites
10Sites

Terminated9Sites

邱昭華

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-06-03 - 2021-02-01

Others

A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

Condition/Disease

Adenocarcinoma of the Stomach
Test Drug

IMU-131

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

Condition/Disease

advanced stage hepatocellular carcinoma
Test Drug

Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2016-10-26 - 2020-12-31

Phase III

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, MultiCenter Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)

Condition/Disease

Heart Failure With Reduced Ejection Fraction (HFrEF)
Test Drug

MK-1242 (vericiguat)

Participate Sites
6Sites

Terminated6Sites

江晨恩

Taipei Veterans General Hospital

2015-04-01 - 2023-12-31

Phase III

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Condition/Disease

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

楊慕華

Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

Condition/Disease

Triple-Negative Breast Cancer
Test Drug

Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2015-03-01 - 2019-04-30

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Condition/Disease

with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates
Test Drug

SGI-110 for subcutaneous injection

Participate Sites
7Sites

Terminated5Sites

高志平

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-09-08 - 2019-10-31

Phase III

A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)

Condition/Disease

Acute Myeloid Leukemia (AML)
Test Drug

Vadastuximab Talirine

Participate Sites
4Sites

Terminated4Sites

蕭樑材

Taipei Veterans General Hospital

Search Result

List